Teprotumumab for the treatment of thyroid eye disease

References

• Perros P, Hegedus L, Bartalena L, et al. Graves’ orbitopathy as a rare disease in Europe: a European group on graves’ orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12(1):72.
   PubMed Web of Science ®Google Scholar
• Paik JS, Kim SE, Kim JH, et al. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy. Immunobiology. 2019;225(2:151902).
   PubMed Web of Science ®Google Scholar
• Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review. Ophthalmol Ther. 2019;9(1):21–33. .
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedüs L, Longo DL. Graves’ disease. N Engl J Med. 2016;375(16):1552–1555.
   PubMed Web of Science ®Google Scholar
• Janssen JAMJL, Varewijck AJ, Brugts MP. The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease. Growth Horm IGF Res. 2019;48-49:16–18.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with graves’ disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178(5):3281–3287.
   PubMed Web of Science ®Google Scholar
• Hwang CJ, Eftekhari K. Teprotumumab for thyroid eye disease. Int Ophthalmol Clin. 2020;60(2): 47–55.
   PubMedGoogle Scholar
• Philippou A, Christopoulos PF, Koutsilieris DM. Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer. Mutat Res Rev Mutat Res. 2017;772: 105–122.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Challenges in orphan drug development: identification of effective therapy for thyroid-associated ophthalmopathy. Annu Rev Pharmacol Toxicol. 2019;59: 129–148.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. TEPEZZA (teprotumumab-trbw) for injection, for intravenous use. [cited 2019 Jan 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf
   Google Scholar
• Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104–106.
   PubMed Web of Science ®Google Scholar
• Genere N, Stan MN. Current and emerging treatment strategies for graves’ orbitopathy. Drugs. 2019;79(2): 109–124.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, European Group on Graves’ Orbitopathy (EUGOGO), et al. The 2016 European thyroid association/European group on graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J. 2016;5(1): 9–26.
   PubMed Web of Science ®Google Scholar
• Kotwal A, Stan M. Current and future treatments for graves’ disease and graves’ ophthalmopathy. Horm Metab Res. 2018;50(12):871–876.
   PubMed Web of Science ®Google Scholar
• Smith TJ. TSHR as a therapeutic target in Graves’ disease. Expert Opin Ther Targets. 2017;21(4): 427–432.
   Web of Science ®Google Scholar
• Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015;6(2):422.
   PubMedGoogle Scholar
• Perros P, Weightman DR, Crombie AL, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122(1):8–12.
   PubMedGoogle Scholar
• Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in TED (CIRTED): a multicentre, 2 × 2 factorial, double- blind, randomized controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299–309.
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe graves’ ophthalmopathy. N Engl J Med. 1989;321(20):1353–1359.
   PubMed Web of Science ®Google Scholar
• Strianese D. Efficacy and Safety of Immunosuppressive agents for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S56–S59.
   PubMedGoogle Scholar
• Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2): 432–441.
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100: 422–431.
   Web of Science ®Google Scholar
• Stan MN, Salvi M. Management of endocrine disease: rituximab therapy for graves’ orbitopathy — lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101–R109.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287–288.
   PubMed Web of Science ®Google Scholar
• Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281–288.
   PubMed Web of Science ®Google Scholar
• Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86(2): 247–255.
   PubMed Web of Science ®Google Scholar
• Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8 +CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2): 89–95.
   PubMed Web of Science ®Google Scholar
• Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in graves orbitopathy study group. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. AJO. 2018;195: 181-190.
   Google Scholar
• Mohyi M, Smith TJ. IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol. 2018;61(1):T29–T43.
   PubMed Web of Science ®Google Scholar
• Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1): 142-150.
   PubMed Web of Science ®Google Scholar
• Smith TJ. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy. Eye (Lond). 2019;33(2):200–205.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Janssen JAMJL. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019;40(1):236–237.
   PubMed Web of Science ®Google Scholar
• Krieger CC, Boutin A, Jang D, et al. Arrestin-β-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk. Endocrinology. 2019;160(6):1468–1469.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedüs L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):291–292.
   PubMed Web of Science ®Google Scholar
• Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99(9):E1635–E1640.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16(8): 2458–2465.
   Web of Science ®Google Scholar
• Smith TJ, Kahaly GJ, Ezra DG, et al., Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 376(18): 1748–1761.
   Web of Science ®Google Scholar
• Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Lond). 2019;33(2): 183-190.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Kahaly GJ, Patel A, et al., Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 382(4):341–342. 2020.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Treatment of graves’ orbitopathy to reduce proptosis with teprotumumab infusions in an open-label clinical extension study (OPTIC-X). [cited 2020 July 2]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03461211?term=teprotumumab&draw=2&rank=1
   Google Scholar
• Smith TJ, Janssen JA. Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy. Front Endocrinol (Lausanne). 2017;7:167.
   PubMed Web of Science ®Google Scholar
• Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of graves’ ophthalmopathy. Exp Eye Res. 2016;142: 83–91
   PubMed Web of Science ®Google Scholar
• Krieger CC, Neumann S, Place RF, et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by graves’ disease immunoglobins. J Clin Endocrinol Metab. 2015;100(3):1071–1077.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Janssen J. Insulin-like growth factor-1 receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2016;40:236–237.
   Web of Science ®Google Scholar
• Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through collaboration study. J Clin Oncol. 2011;29(34):4541–4547.
   PubMed Web of Science ®Google Scholar
• Pappo AS, Vassal G, Crowley JJ, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a sarcoma alliance for research through collaboration study. Cancer. 2014;120(16): 2448–2456.
   PubMed Web of Science ®Google Scholar